期刊文献+

新辅助化疗与间隔性减灭术联合艾迪注射液对卵巢上皮癌患者的预后影响

下载PDF
导出
摘要 目的研究新辅助化疗联合间隔性减灭术联合艾迪注射液对卵巢上皮癌患者预后的影响。方法将2011年3月至2013年12月期间我院收治的晚期卵巢上皮癌患者90例纳入研究对象,根据减灭术治疗方法不同分为接受新辅助化疗联合间隔性减灭术联合艾迪注射液的观察组和接受新辅助化疗联合单次减灭术的对照组,比较两组患者的存活情况及生存质量。结果 1存活情况:术后1年、2年、3年时,观察组患者的存活率均高于对照组;2生存质量:观察组患者的自我实现、健康责任、运动、营养、人际关系、应对压力评分均高于对照组。结论新辅助化疗与间隔性减灭术联合艾迪注射液有助于延长生存时间、提高生存率,同时改善生存质量,是卵巢上皮癌患者理想的治疗方法。
出处 《环球中医药》 CAS 2014年第S1期29-30,共2页 Global Traditional Chinese Medicine
  • 相关文献

参考文献6

二级参考文献35

  • 1Robert J,Morgan J, Ronald D. NCCN clincal practice guide- lines in oncology, Ovarian Cancer, including fallopian tube tumor and primary peritoneal cancer[ Z] .2011.
  • 2Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 pa- tients [ J ]. Gynecol Oncol, 1998,71 ( 3 ) :431-436.
  • 3Everett EN, French AE, Stone RL,et al. Initial chemother- apy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer [ J]. Am J Obstet Gynecol,2006,195 (2) :568-576.
  • 4Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma[ J]. World J Surg Oncol,2005,3 ( 1 ) :57-64.
  • 5Lee SJ, Kim BG, Lee JW,et al. Preliminary results of neo- adjuvant chemotherapy with paclitaxel and cisplatin in pa- tients with advanced epithelial ovarian cancer who are in- adequate for optimum primary surgery [ J ]. J Obstet Gynaecol Res ,2006,32( 1 ) :99-106.
  • 6Inciura A, Simavicius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the manage- ment of advanced ovarian cancer : a retrospective study of 574 patients [ J ]. BMC Cancer,2006,8 (6) : 153.
  • 7Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gyneco- logic oncologists treating advanced epithelial ovarian cancer? [ J ]. Gynecol Oncol,2001,82 (3) :489-497.
  • 8van der Burg ME,van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gyneco- logical Cancer Cooperative Group of tire European Organi- zation for Research and Treatment of Cancer[ J ]. N Engl J Med, 1995,332(10) :629-634.
  • 9Rose PG, Nerenstone S, Brady MF, et al. Secondary sur- gical cytoreduction for advanced ovarian carcinoma[ J ]. N Engl J Med,2004,351 (24) :2489-2497.
  • 10Lee SJ,Kim BG,Lee JW,et a1.Preliminary results of neoadjuvantchemotherapy with paclitaxel and eisplatin in patients with advancedepithelial ovarian cancer who age inadequate for optimum Pdmarysurgery[J].J Ohstet Gynaeool Res,2010,32(7):99-106.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部